What Makes Asia Appealing For Clinical Trials?
Asia is continuing to emerge as a global hot spot for clinical trials, helped by positive factors including patient availability and competitive costs, but challenges remain, a recent conference in Seoul heard.
You may also be interested in...
Green Cross has overhauled the global development strategy for its hemophilia A therapy GreenGene F, halting slow-progressing Phase III trials in the US and Europe and shifting its focus instead to the fast-growing China market.
As well as establishing the benefits of lower dosing, new results from a multinational clinical trial with clot-buster alteplase have highlighted the strong performance of Asian study sites, breaking some perceptions in the process.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.